Key facts
as of Sep 2026- Freenome’s last known valuation is $2.2B (Feb 2024).
- It has raised $1.4B across 3 recorded rounds; the latest was PIPE ($240.0M) in Dec 2025.
- Notable investors include Andreessen Horowitz, RA Capital Management, GV, Founders Fund, DCVC — 53 tracked in total.
- 3 institutional filers report fund marks on Freenome across 26 filings.
- Status: Privately Held (backing).
PA Mark — composite indicative price
LOW confidence~$3per share
as of Sep 2026 · the exact daily mark is a member feature
Free account
See the evidence behind this price
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 53 names
- ·Watchlist + deal alerts for Freenome
Create free account
No card required
Recorded secondary trades
No prints on record
No secondary trades in Freenome shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
3 filers · latest May 20263 SEC-registered funds reported 26 fair-value marks on Freenome between Apr 2025 and May 2026. Filer-level marks and implied $/share are available to Pro members.
Funding rounds
3 roundsDec 2025PIPE$240.0M▮
Feb 2024Later Stage VC (Series F)$254.0M▮
Dec 2021Later Stage VC (Series D)$300.0M▮
About Freenome
Developer of a multi-omics platform designed to detect cancer at an early stage through a routine blood draw. The company's platform uses a proprietary algorithm method that aims to reinvent disease management through systematized early detection and intervention of disease screenings, enabling doctors to treat cancer and other diseases at manageable stages.
- Industry
- Decision/Risk Analysis
- Sector
- Healthcare
- HQ
- Brisbane, CA, United States
- Founded
- 2014
- Employees
- 392
- Website
- freenome.com/
- Ownership
- Privately Held (backing)